Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial (Q31826097)
scientific article
Language:
Current Data About Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial
(P31) (Q13442814)
(P248)
(P698) 11157009
(P813) Tuesday, July 4, 2017

(P304) 602-611
(P248)
(P698) 11157009
(P813) Tuesday, July 4, 2017

(P407) (Q1860)

(P433) 3
(P248)
(P698) 11157009
(P813) Tuesday, July 4, 2017

(P478) 19
(P248)
(P698) 11157009
(P813) Tuesday, July 4, 2017

(P577) Thursday, February 1, 2001
(P248)
(P698) 11157009
(P813) Tuesday, July 4, 2017

(P921) (Q974135)

(Q128581)
(P887)

(P1433) (Q400292)
(P248)
(P698) 11157009
(P813) Tuesday, July 4, 2017

(P1476) "Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial" (language: en)
(P248)
(P698) 11157009
(P813) Tuesday, July 4, 2017

(P2093) French Adjuvant Study Group
(P1545) 1
(P248)
(P698) 11157009
(P813) Tuesday, July 4, 2017

other details
description scientific article

External Links
(P356) 10.1200/JCO.2001.19.3.602
(P698) 11157009